Lord, Abbett & Co
RNAM

Lord, Abbett & Co’s Avidity Biosciences RNAM Stock Holding History

Lord, Abbett & Co’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-539,207
Closed -$24.8M – 574
2024
Q3 		$24.8M Buy
539,207
+124,867
+30% +$5.42M 0.08% 292
2024
Q2 		$16.9M Buy
+414,340
New +$11.9M 0.06% 342

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co's RNAM Position: Q4 2024 in Review

Lord, Abbett & Co sold out of Avidity Biosciences (RNAM) in Q4 2024, closing a stake of 539,207 shares — an estimated $24.8M sold.

Lord, Abbett & Co first reported a position in RNAM in Q2 2024 and held it in 2 quarters. The position peaked at $24.8M in Q3 2024. 236 funds tracked by Wall St. Rank hold RNAM as of Q4 2024.

  • Lord, Abbett & Co reported no remaining Avidity Biosciences position as of Q4 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 539,207 Avidity Biosciences shares in Q4 2024, an estimated $24.8M.
  • Lord, Abbett & Co first reported a position in Avidity Biosciences in Q2 2024 and held it in 2 quarters.
  • Lord, Abbett & Co's Avidity Biosciences position peaked at $24.8M in Q3 2024.
  • 236 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2024.

Based on Lord, Abbett & Co's 13F filing for Q4 2024, filed 14 Feb 2025.